Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) was up 4% during trading on Tuesday . The company traded as high as $5.35 and last traded at $5.25. Approximately 113,542 shares were traded during trading, a decline of 92% from the average daily volume of 1,391,078 shares. The stock had previously closed at $5.05.
Dominari Stock Performance
The firm's fifty day moving average price is $4.67 and its 200 day moving average price is $3.56. The firm has a market cap of $87.72 million, a P/E ratio of -1.55 and a beta of 0.59.
Dominari (NASDAQ:DOMH - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share (EPS) for the quarter. The business had revenue of $6.56 million for the quarter. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%.
Dominari Dividend Announcement
The company also recently declared a dividend, which was paid on Monday, March 3rd. Shareholders of record on Monday, February 24th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Monday, February 24th.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Dominari stock. Renaissance Technologies LLC raised its holdings in shares of Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,326 shares of the company's stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned 0.89% of Dominari worth $55,000 at the end of the most recent quarter. 42.48% of the stock is currently owned by hedge funds and other institutional investors.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Further Reading
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
